This overexpression was particularly pronounced in samples from prostate cancer patients resistant to DTX treatment, as depicted in Figs. 3E, H, and Supplementary Figure S3H, I. Consistently, there was a higher IL-11/IL-11RA protein level in the tissues of patients with PCA with docetaxel resistance/biochemical recurrence than in those of patients without docetaxel resistance/biochemical recurrence (Fig. 3I, J). The gene discussed is IL11; the disease is prostate carcinoma.